KEG aQ7e p fet 4
DEC 1 6 2008
510(k) Summa
Global USA Distribution, LLC
SkinClear Q-Switched Nd:YAG Laser
Submitter: Global USA Distribution, LLC
Address: 10723 Aquila Av. S.
Minneapolis, MN 55438
Contact Person: Matt Makousky
Telephone: 952-703-5373
Facsimile: 952-888-8887
Date Prepared: July 1, 2008
Device Trade Name: SkinClear Q-Switched Nd:YAG Laser
Classification Name: Instrument, Powered, Laser
Legally Marketed Predicate Devices: Sandstone Medical Technologies, LLC
UltraLight II Nd:YAG Laser System (K041011)
Description of the SkinClear Q-Switched Nd:YAG Laser:
The SkinClear Q-Switched Nd:YAG Laser is composed of a console which houses a
power supply, electronic circuit board, cooling system,.a liquid crystal display screen
(LCD), a handpiece which contains the light source which is connected to the console by
a power cord, and an on/off footswitch.
Intended Use of the : SkinClear Q-Switched Nd:YAG Laser:
The SkinClear Q-Switched Nd:YAG Laser is indicated at the 1064 nm wavelength for
dark ink tattoo removal, the removal of pigmented lesions, and the removal or lightening
of hair. Indicated for use on all skin types (Fitzpatrick I-IV).
The SkinClear Q-Switched Nd:YAG Laser is indicated at the 532 nm wavelength for red
ink tattoo removal, treatment of vascular lesions including facial and leg veins,
telangiectasias, angiomas, hemangiomas, port wine stains, and most pigmented lesions
(e.g. lentigines, ephildes). Indicated for use on all skin types (Fitzpatrick I-IV).

, Kor 3 LIZ gp ert &
wD & fo

Summary of technological characteristics:

The SkinClear Q-Switched Nd:YAG Laser and the Sandstone Medical Technologies,

LLC UltraLight II Nd:YAG Laser System share the same wavelengths, energy output,

pulse duration, and pulse repetition rate.

Nonclinical Performance

Data: None

Clinical Performance

Data: None :

Additional Information: None requested at this time

Conclusion: The SkinClear Q-Switched Nd:YAG Laser is
substantially equivalent to other existing legally ‘
marketed laser systems currently in commercial
distribution.

2 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
s a
ae Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
Global USA Distribution, LLC
% Underwriters Laboratory, Inc. DEC 1 6 2008
Mr. Ned Devine
333 Pfingsten Road ,
Northbrook, Hlinois 60062
Re: K083272
Trade/Device Name: SkinClear™ Q-Switched Nd:YAG Laser System
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery
and in dermatology : .
Regulatory Class: II
Product Code: GEX
Dated: December 3, 2008
Received: December 4, 2008
Dear Mr. Devine:
We have reviewed your Section 510(k) premarket notification of intent to market the device :
referenced above and have determined the device is substantially equivalent (for the indications’
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of : :
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration. :
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and-regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set:

Page 2 - Mr. Ned Devine
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device.to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance at ‘
(240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification” (21CFR Part 807.97). For questions regarding postmarket surveillance,
please contact CDRH’s Office of Surveillance and Biometric’s (OSB’s) Division of Postmarket
Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events
(Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems .
at (240) 276-3464, You may obtain other general information on your responsibilities under the
Act from the Division of Small Manufacturers, International and Consumer Assistance .
at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address
http://www. fda.gov/cedrh/industry/support/index.html.
; Sincerely yours,

Mark N. Melkerson

Director .

Division of General, Restorative

: and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health .
Enclosure .

KOF327D ce bet
Indications for Use: : :
510(k) Number (if known): __Device Name: SkinClear™ Q-Switched Nd:YAG Laser System
Indications for Use: oo
The SkinClear Q-Switched Nd:YAG Laser is indicated at the 1064:nm
wavelength for dark ink tattoo removal, the removal of pigmented lesions,
. and the removal or lightening of hair. Indicated for use on all skin-types . .
(Fitzpatrick I-IV)
The SkinClear Q-Switched Nd:YAG Laser is indicated at the 532 nm
wavelength for red ink tattoo removal, treatment of vascular lesions
including facial and leg veins, telangiectasias, angiomas, hemangiomas, port
wine stains, and most pigmented lesions (e.g. lentigines, ephildes).
. Indicated for use on all skin types (Fitzpatrick I-IV)
Prescription Use: . X AND/OR  Over-The-Counter Use

(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

' (Please do not write below this line — Continue on another page if needed)

. Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign- oo
Division of General, Restorative,
= and Neurological Devices .,
$10) Number__K 993277 |

